Therapeutic Focus

Immune-oncology (IO) is the practice of using and stimulating the body's own immune system to recognise and destroy tumour cells. Unlike conventional chemotherapy, which attacks cancer cells directly, IO approaches work by removing the "brakes" on immune response, by enhancing T-cell activation, or by engineering immune cells to seek and destroy specific tumour antigens.

Medyra Health's immune-oncology programmes focus on checkpoint inhibition biology (PD-1/PD-L1, CTLA-4), tumour microenvironment modulation, and combination strategies that pair IO agents with targeted therapies or other biologics. Patient selection through biomarker stratification — including PD-L1 expression, tumour mutational burden (TMB), and microsatellite instability (MSI) — is central to all IO programme design at Medyra Health.

Evidence-led focus means that Medyra Health does not pursue mechanisms, targets, or programmes without a credible, peer-reviewed scientific rationale and a clearly demonstrable unmet patient need. In a field where enthusiasm often runs ahead of data, we believe rigorous evidence synthesis is a competitive advantage — not a constraint.

Our evidence review processes draw on systematic literature analysis, expert advisory panels, and structured competitive intelligence to ensure that every programme Medyra Health advances has the scientific foundation required to withstand the scrutiny of regulators, clinical investigators, and partner organisations. We do not invest in scientific fashion; we invest in evidence-anchored opportunity.

Gene therapy — the delivery of therapeutic genetic material to correct, silence, or replace a dysfunctional gene — holds transformative potential for conditions with defined genetic aetiologies. The approval of multiple gene therapies for rare diseases over the past decade has validated the field and established the regulatory frameworks now being applied to next-generation programmes in larger patient populations.

Medyra Health's gene therapy thinking spans viral vector selection and optimisation (AAV serotype selection, lentiviral vector design, next-generation capsid engineering), payload design (promoter selection, transgene optimisation, regulatory element design), delivery mechanism considerations (local versus systemic administration, route of delivery, dose), and the manufacturing process development required to produce clinical and commercial quantities of gene therapy product under GMP conditions.

Diabetes affects over 530 million people worldwide and is projected to reach 640 million by 2030. Type 2 diabetes accounts for approximately 90% of cases and is closely linked to obesity, physical inactivity, and an ageing population. Type 1 diabetes, an autoimmune condition, requires lifelong insulin therapy and carries significant quality-of-life burden even with modern management. Both types carry substantial risks of cardiovascular disease, renal failure, neuropathy, and retinopathy if insufficiently controlled.

Medyra Health's diabetes focus encompasses both therapeutic development pathways and healthcare system support tools. On the therapeutic side, our programmes focus on novel insulin formulations, GLP-1 receptor agonist delivery optimisation, and combination approaches that address both glycaemic control and cardiovascular risk reduction. On the system support side, we design evidence frameworks and clinical decision tools that help primary care and specialist teams manage diabetes more effectively at population scale.

Medication non-adherence costs healthcare systems an estimated $300 billion annually in the US alone and is responsible for approximately 125,000 preventable deaths per year in chronic disease settings. In diabetes, non-adherence to insulin therapy is one of the leading causes of preventable hospitalisation, end-organ damage, and premature mortality. Medyra Health designs adherence by design into every cardiometabolic programme — treating it as a core therapeutic attribute rather than a post-launch intervention.

Access — the ability of patients to actually obtain and afford the therapies they need — is the other half of the real-world outcomes equation. Medyra Health integrates market access planning, health technology assessment (HTA) strategy, and equitable distribution frameworks into every programme from the earliest stages of development, ensuring that clinical success translates into patient benefit at scale.

A care pathway is a structured, multidisciplinary plan that defines the sequencing and timing of key clinical interventions for a specific patient group. Well-designed care pathways reduce unwarranted clinical variation, improve evidence-based prescribing, and — critically — improve patient outcomes by ensuring that the right interventions happen at the right time for every patient, regardless of which clinician or care setting they encounter.

Medyra Health designs care pathways for neurodegenerative conditions that span the full disease arc — from pre-symptomatic risk assessment and screening, through diagnosis, pharmacological and non-pharmacological management, and transition to palliative and end-of-life care. Our pathways are designed to be practically implementable in resource-constrained NHS and international healthcare settings — not theoretical ideals that require unrealistic staffing or infrastructure.

Urinary tract infections are among the most common bacterial infections managed in healthcare settings globally, accounting for approximately 150 million consultations annually worldwide. In the UK, UTIs account for around 1–3% of all GP consultations and are the most common reason for antibiotic prescribing in primary care. In care homes and hospitals, UTIs are a leading cause of avoidable hospitalisation, sepsis, and antibiotic-resistant infection — with the associated costs and patient safety risks that follow.

Medyra Health's UTI focus encompasses point-of-care diagnostic tool integration, evidence-based treatment protocol design, antimicrobial stewardship framework development, and recurrence prevention programmes — addressing the full UTI episode from symptom presentation through treatment, monitoring, and prevention of recurrence in high-risk populations.

Optimising infectious disease care in community and care settings requires more than better diagnostics and better treatments — it requires systemic change in the care environment itself. Medyra Health's care optimisation frameworks address the environmental, behavioural, and organisational factors that drive infection rates in care homes, community hospitals, and primary care networks — reducing infection incidence, limiting antibiotic exposure, and improving outcomes for the most vulnerable patient populations.

Our care optimisation programmes are designed to be practical, scalable, and evidence-based — drawing on infection prevention and control (IPC) best practice, antimicrobial stewardship programme design, staff education frameworks, and environmental hygiene assessment to deliver measurable reductions in healthcare-associated infection rates without requiring major infrastructure investment.

Clinical intelligence is the transformation of raw clinical and operational data into interpretable, actionable outputs that support better clinical and managerial decision-making. Medyra Health's clinical intelligence capability is built on the principle that analytical outputs must be designed for their end user — clinicians, commissioners, and operational managers who need clear answers, not complex statistical models requiring specialist interpretation.

Our clinical intelligence frameworks cover outcome measurement strategy, clinical performance monitoring, patient pathway analytics, and population health management tools — all designed to run in real NHS and international healthcare environments, not idealised data environments with perfect data completeness and standardisation.